GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » Tax Expense

Microbix Biosystems (TSX:MBX) Tax Expense : C$0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems Tax Expense?

Microbix Biosystems's tax expense for the months ended in Jun. 2024 was C$0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Jun. 2024 was C$0.00 Mil.


Microbix Biosystems Tax Expense Historical Data

The historical data trend for Microbix Biosystems's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems Tax Expense Chart

Microbix Biosystems Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 1.57 - 0.08 -

Microbix Biosystems Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Microbix Biosystems Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbix Biosystems  (TSX:MBX) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Microbix Biosystems Tax Expense Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.
Executives
Cameron Lionel Groome Director, Senior Officer
Bo Hollas Director
Steven Trevor Hagerman Senior Officer
Jennifer Anne Stewart Director
James Stuart Currie Senior Officer
Damian Klimaszewski Senior Officer
Kenneth Hughes Senior Officer
Anthony J. Giovinazzo Director
Martin Marino Director
Mark Adrian Luscher Senior Officer
Peter Martin Blecher Director